Sanofi India Recommends Final Dividend of ₹48/Share; Sets Record Date for April 22
Sanofi India recommended a final dividend of ₹48 per equity share for FY25, subject to shareholder approval at the AGM. The record date for dividend eligibility is April 22, 2026. Shareholders must update their details by this date for TDS compliance. Physical dividend warrants will be discontinued from November 19, 2025.
The dividend payout is a material event for shareholders. The detailed information on TDS and the discontinuation of physical warrants also requires attention from investors and impacts the administrative process.
The announcement of a dividend payment is generally viewed positively by shareholders as it represents a return on their investment.
Sanofi India Limited has announced its final dividend recommendation for the financial year ended December 31, 2025. The Board of Directors, in a meeting held on February 25, 2026, proposed a final dividend of ₹48 per equity share of ₹10 each.
This dividend is subject to the approval of the shareholders at the upcoming 70th Annual General Meeting (AGM). The payment will be made to those shareholders whose names appear in the Company's Register of Members or as beneficial owners as of the close of business hours on April 22, 2026, which has been set as the Record Date.
The company has also provided detailed communication regarding Tax Deduction at Source (TDS) on the final dividend. Shareholders are urged to ensure their PAN, residential status, email address, and bank account details are updated with the company's Registrar and Transfer Agent (RTA) or their depository participant by the Record Date, April 22, 2026. The last date for submitting TDS declarations (Form 15G/15H) is April 15, 2026, by 5:00 pm IST.
Furthermore, in line with SEBI regulations effective November 19, 2025, Sanofi India Limited will discontinue the issuance of physical dividend warrants or cheques. All future dividend payments will be exclusively processed through electronic modes like NEFT, RTGS, or NECS. Shareholders are advised to update their bank account details promptly to ensure timely credit of dividends.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.